Document:

EX-10.33

 Exhibit 10.33 
  

 

 
 Project no. 850226/30000 TICK/SAI 
  

 Funding contract 

agreed between 

Österreichische Forschungsförderungsgesellschaft mbH (FFG) 

as funding donor 
 and 

ARSANIS Biosciences GmbH 

Helmut-Qualtinger-Gasse 2 
 1030
Vienna 
 Company register number 354305m 

as funding recipient. 
 1
Awarding of the funding 
  

			
	1.1	  	Based on the funding application “KLIPHA: GMP manufacturing and Phase 1 testing of 2 human monoclonal antibodies against S. aureus infections” submitted via eCall on 2/2/2015 and based on the professional decision of the
advisory board during the session of 5/13/2015, a funding for the following project is awarded
		
		  	 Project number: 850226
 eCall number:
5492068
 Project name (subject of the agreement):

							
		 		 	Program:	  	 KLIPHA: GMP manufacturing and Phase 1 testing of 2 human monoclonal antibodies against S. aureus infections.

Basic program

  
 ./2 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna                 
	  	 Tel+43 (0)5 7755-0
 Fax+43 (0)5 7755 -97900

www.ffg.at, office@ffg.at
 FN 252263a HG Vienna
	  	

			
		  	 

	Page 2	  	Project no. 846178/30000 SCK/SAI

  

 2 Project duration 

 

	2.1	The overall project duration begins on 2/2/2015 and ends on 1/31/2017. 

  

	2.2	The granting of the entire project by the FFG is dependent on the results of the submitted reports, the continued fulfillment of the evaluation and decision criteria, the budget available to the grant donor, as well as
a renewed positive funding decision. 

 3 Funding period 

 

	3.1	The objective funding period of the project begins on 2/2/2015 as acceptance deadline and ends on 1/31/2017 

4 Type and level of funding 
  

	4.1	The funding is provided in the following form for the funding period specified in section 3: 

  

					
	 Funding form
	  	Amount 
up to max.	 
	 FFG loan
	  	EUR	1,500,000.00	 

  

			
	Loan conditions	  	
		
	Interest rate	  	0.75% p.a. on current account basis
		
	Repayment date:	  	on 3/31/2022
		
	Repayment amount:	  	EUR 1,500,000.00
		
	Interest and loan collection	  	in direct debit
		
	Interest stipulation:	  	half-yearly in retrospect or on loan maturity

  

	4.2	The funding quota of the project amounts to 50.0% of the demonstrable and eligible project costs. The remaining funding of the project costs is the responsibility of the funding recipient. Based on the planning data,
the funding cash value amounts to EUR 237,065.00, that is 7.9% related to the eligible costs according to point 5.1. 

  

	4.3	The maximum aid intensity according to the current Union state aid framework for the funding of research, development and innovation amounts to 45.0%. 

 

	4.4	The consequence of the shortfall of the eligible project costs is an aliquot reduction of the funding. 

  

	4.5	The eligible project costs according to section 5 as well the costs reported through interim and final settlements do not represent any cost acknowledgment before an assessment by the FFG. The final amount of the
eligible total project costs as well as the funding are determined only after completion of the project during invoice verification. 

  
 ./3 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel+43 (0)5 7755-0
 Fax+43 (0) 5 7755 -97900

www.ffg.at, office@ffg.at
 FN 252263a HG Vienna
	  	

			
		  	 

	Page 3	  	Project no. 846178/30000 SCK/SAI

  

 5 Eligible costs 

 

	5.1	The funding is subject to the following eligible project costs: 

  

					
	 Personnel costs
	  	EUR	292,600.00	 
	 General and material costs
	  	EUR	21,800.00	 
	 Third-party services
	  	EUR	2,683,900.00	 
	 Travel expenses
	  	EUR	1,700.00	 
		  	  
	  
	 
	 Total eligible costs
	  	EUR	 3,000,000.00	 

  

	5.2	Eligible costs are all those costs attributable to the project that result directly, actually and additionally from the usual operating costs for the duration of the funded research activity according to Article 3.
Additional supplementary provisions to the eligible costs can arise from the FFG “KMU” guidelines, the cost guidelines and the Single Project Experimental Development guidelines (each in the version specified under 14.1).

  

	5.3	Substantial changes to the cost structure require the prior written approval of the FFG. 

  

	5.4	The sales tax levied on the costs of the service is not eligible. In so far as this sales tax demonstrably and finally is to be borne by the funding recipient and consequently no
pre-tax deduction is applicable for him/her, it is taken into account as an eligible cost component. 

Funding by the funding donor constitutes a real grant that is not subject to sales tax, since no exchange of services takes place, but there is
public interest in carrying out the research project. 
 The funding amount is a gross amount. An additional separate sales tax settlement is
- for whatever legal reason - excluded. 
 The loan interest/guarantee commissions are exempt from sales tax according to Article 6 para. 1
line 8 UStG (Umsatzsteuergesetz) [sales tax law] 
  

	5.5	If the amortization period of an item (section 285 ABGB) purchased to carry out the project exceeds the funding period, the depreciation costs are eligible in the manner specified according to the Single Project
Experimental Development guidelines and in the cost guidelines (each in the version specified under 14.1). 

  

	5.6	The funding means of the funding donor must not be used for the creation of reserves and provisions according to BGBI no. 400/1998 of the income tax law. The funding means must be used only for the services and
objectives set out in the funding request. 

  

	5.7	The costs incurred by the funding recipient or his/her partners from preparation of the contract, or any transfer charges, must be borne by these parties and do not constitute eligible costs. 

 

	5.8	The funding donor reserves the right to defer, reduce or suspend payment of funding, if and as long as circumstances are such that the orderly execution of the sponsored project appears not to be guaranteed (e.g. the
cost justification is not provided as planned). 

  
 ./4 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel+43 (0)5 7755-0
 Fax+43 (0) 5 7755 -97900

www.ffg.at, office@ffg.at
 FN 252263a HG Vienna
	  	

			
		  	 

	Page 4	  	Project no. 846178/30000 SCK/SAI

  

 6 Conditions and requirements 

 

	6.1	Project-specific special conditions and requirements 

  

	 	1.	Before payment of the 1st, a “safety assessment of the mAK” must be submitted. 

 

	 	2.	Before payment of the 1st, a vote of approval from the Ethics Committee must be provided. 

 

	 	3.	The maximum eligible costs within the framework of KLIPHA amount 3 million. The third party costs were therefore correspondingly reduced. 

 

	 	4.	For the GMP material, a unique usage certificate for the current KLIPHA project “ASN100 Phase 1 Study” must be created. 

  

	6.2	The originally signed funding contract must be returned to the funding donor no later than 4 weeks after receipt. 

  

	6.3	By signing this funding contract, the funding recipient confirms that he/she—at the latest in the course of the planned reports—is aware of all requested and/or approved official subsidies that directly or
indirectly concern the project. 

 7 Payment of the funding 

 

	7.1	The specified funding is transferred in accordance with the following payment plan: 

  

					
	 On contract completion:
	  	€	750,000.00	 
	 after presentation and approval of the interim report and interim settlement on the deadline
3/31/2016
	  	€	450,000.00	 

 Payment of the final installment in the amount of €300,000.00 follows after fulfillment of all conditions
and requirements (final settlement, final reports, etc.) and after inspection and approval of the usage certificate (relief) by the FFG. 
 7.2 The transfer
is made to the following account of the funding recipient 
  

			
	 Account owner:    

Bank name:
 IBAN:

BIC/SWIFT:
	 	 ARSANIS Biosciences GmbH

 8 Reporting obligations 
  

	8.1	The funding recipient must report the implementation of the funded project by submitting technical reports (interim and final reports) and settlements to the FFG according to point 3 of the General Funding Conditions.
Reporting and accounting must take place via eCall (https://ecall.ffg.at). Use of the forms defined in eCall is mandatory. Further documents must be made available to the FFG on request. 

 

	8.2	With a funding of prototypes, the funding recipient must report any retention or further use of the prototype(s) to the FFG. 

  
 ./5 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel+43 (0)5 7755-0
 Fax+43 (0) 5 7755 -97900

www.ffg.at, office@ffg.at
 FN 252263a HG Vienna
	  	

			
		  	 

	Page 5	  	Project no. 846178/30000 SCK/SAI

  

 9 Contract changes 

 

	9.1	Changes to the current contract can be only made in written form. This applies also to a departure from this provision. 

  

	9.2	If necessary, subsequent changes to the agreed conditions and requirements can be made under special circumstances by mutual agreement in the form of written additional agreements, after reconsideration by the advisory
board. 

 10 Liability 
  

	10.1	The funding recipient must be liable without limit to the FFG for adherence to all contractual conditions. The funding recipient is also liable for the behavior of third parties for whom he/she is responsible (e.g.
owners, corporate bodies, etc.). The funding recipient indemnifies and holds the FFG harmless against the claims of third parties. 

11 Severability clause 
  

	11.1	If a provision of this funding contract proves ineffective, the effectiveness of the remaining provisions of the funding contract are not affected. The contracting parties undertake to replace an ineffective provision
by a provision that comes closest to the purpose of the contract. 

 12 Applicable law 

 

	12.1	This contract and all its annexes are subject to Austrian law excluding the reference provisions of the Austrian IPRG [International Private Law Act]. 

13 Jurisdiction 
  

	13.1	The competent court in Vienna has jurisdiction in all litigation arising from the granting of funds. The FFG also retains the right to sue the funding recipient in his/her general jurisdiction. 

14 Contract components 
  

	14.1	The following documents are the integral elements of the funding contract: 

  

	 	•	 	the funding request (“KLIPHA: GMP manufacturing and Phase 1 testing of 2 human monoclonal antibodies against S. aureus infections.”) in the version of 5/5/2015 submitted via eCall 

 

	 	•	 	General funding conditions for funding contracts in the current version (2015) 

  

	 	•	 	Guidelines for Single Project Experimental Development, Version 3.0 

  

	 	•	 	Cost guidelines, Version 2.0 

  

	14.2	The following are regarded as the legal basis of this funding contract: 

  

	 	•	 	Österreichische Forschungsförderungsgesellschaft mbH establishment act (research funding, structure reform act) in the currently applicable version 

  
 ./6 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel+43 (0)5 7755-0
 Fax+43 (0) 5 7755 -97900

www.ffg.at, office@ffg.at
 FN 252263a HG Vienna
	  	

			
		  	 

	Page 6	  	Project no. 846178/30000 SCK/SAI

  

	 	•	 	Union state aid framework for the funding of research, development and innovation (ABI. C 198 of 6/27/2014) 

  

	 	•	 	(EU) Commission Implementing Regulation no. 651/2014 of June 17, 2014 declaring the compatibility of certain categories of aid with the internal market in application of Articles 107 and 108 of the contract on the
operation of the European Union (AGVO 2014) 

  

	 	•	 	Guideline for the Österreichische Forschungsförderungsgesellschaft mbH for the funding of applied research, development and innovation (FFG guideline “KMU” GZ: BMVIT- 609.986/0012- 111/12/2014 und BMWFW-98.310/0102-C1/10/2014)—This guideline was registered for release with the European Commission on the basis of AGVO 2014. 

The funding recipient confirms his/her awareness of all contract components and accepts them without reservation and takes note that non-compliance with the specified contract requirements may lead to the funding being recovered. 
 The funding recipient
confirms that no recovery order of the European Commission is currently outstanding and any withdrawal of the incompatible funding is excluded. 
 The
funding recipient agrees that the data listed according to Article 9 para. 1 AGVO (VO EU no. 651/2014) annex III is used for the publication of information, as long as the cash value of the funding (gross grant-equivalent) exceeds €500,000.00.

 For the funding donor: 
 Österreichische
Forschungsförderungsgesellschaft mbH (FFG)      
 [seal:]     

Austrian Research Promotion Agencry mbH (FFG) 

Vienna, on 7/6/2015 
  

					
	 /s/ Dr. Henriette Egerth-Stadlhuber
	  		  	 /s/ Dr. Klaus Pseiner

	 Dr. Henrietta Egerth-Stadlhuber
 Managing
Director
	  		  	 Dr. Klaus Pseiner
 Managing
Director

 Funding recipient 

Vienna, on 7/20/2015 
  

			
	 /s/ Dr. Eszter Nagy

Dr. Eszter Nagy
 Managing Director

 
	  	 ARSANIS

Biosciences GmbH
 MarxBox

Helmut-Qualtinger-Gasse 2
 1030
Vienna

 (Add company signature, name and position in block letters, company stamp) 

  
 ./7 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Phone +43 (0)5 7755-0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

			
	  
 Page 7
	  	 FFG        

Project no. 846178/30000 SCK/SAI

  

 Attachments: 

Guideline for the Österreichische Forschungsförderungsgesellschaft mbH for the funding of applied research, development and innovation (FFG
guideline “KMU”) 
 as per https://www.ffg.at/recht-finanzen/rechtsgrundlagen 

General funding conditions for funding contracts in the current version (2015) 

Guidelines for Single Project Experimental Development, Version 3.0 

Cost guidelines, Version 2.0 

  
 ./8 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Phone +43(0)5 7755 -0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a HG Vienna
	  	

 

 
  

 ARSANIS Biosciences GmbH 

Attention Dr. Eszter Nagy 
 Helmut-Qualtinger-Gasse
2 
 1030 Vienna 
 Account
statement of 11/12/2015 
 Project 850226 

KLIPHA: GMP manufacturing and Phase 1 testing of 2 human monoclonal 

antibodies against S. aureus infections. 
  

					
	 Account no.:    
 Financial
year:    
 Redemption amount (EUR):    

Repayment date:    
 Interest
rate:    
	  	 
 
 

 
	18502260
 2015

750,000.00
 3/31/2022

0.75%
	 
  
  

 
  

  
  

							
	Balance on 12/31/2014 (EUR)	  	0.00	 
			
	 Document date
	  	 Posting text
	  	Transaction amount (EUR)	 
			
	11.12.2015	  	 850226 DA rate 1 BP basis
	  	 	-750.000,00	 
			
		  	 Total debits (EUR)    
  

Total credits (EUR)    
	  	   
 
	 750,000.00 
 0.00
	   
  

			
		  	Balance on 11/12/2015 (EUR)	  	 	750,000.00	 

  
  

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna                 
	  	 Phone +43 (0)5 7755-0
 Fax+43 (0)5 7755-97900

www.ffg.at, office@ffg.at
 FN 252263a HG ViennaEX-10.34

 Exhibit 10.34 

 
 

 
 Project number 856836 /30000 MAB/SAH 

 

 Funding Agreement 

between 

Österreichischen Forschungsförderungsgesellschaft mbH (FFG) 

as the funding agency 
 and 

ARSANIS Biosciences GmbH 

Helmut-Qualtinger-Gasse 2 
 1030
Vienna 
 Co. Reg. 354305m 
 as
the funding recipient. 
 Section 1 Award of Funding 
  

	1.1	Based on the research proposal “Development of antibody-based therapeutics for the treatment of life-threatening pneumococcal disease” submitted via eCall on 05/12/2016, and based on the expert decision of the
Advisory council meeting on 06/27/2016. a grant is being made for the following project: 

  

			
	Project number:	  	856836
	eCall number:	  	7848218
	Previous project number:	  	851485
	Project name (The subject of the agreement):
		  	Development of antibody-based therapeutics for the treatment of life threatening
		  	pneumococcal disease
	Program:	  	Basic program

  

  
 ./2 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43 (0)5 7755 - 0
 Fax +43 (0)5 7755 -
97900
 www.ffg.at.office@ffg.at
 Reg. Co.252263a Vienna Comm.
Court
	  	

 

 

			
	 Page 2
 number 856836/30000
	  	Project        

  

 Section 2 Project Duration 

 

	2.1	The total project duration is from 02/01/2013 until 04/30/2017. 

  

	2.2	The grant for the entire project from FFG depends on visible results from submitted reports, continued compliance with the evaluation and decision-making criteria, also on the budget available to the granting body, and
on a further positive funding decision. 

 Section 3 Funding Period 

 

	3.1	The current funding period of the project starts on 05/01/2016 as the date of award and ends on 04/30/2017. 

Section 4 Type and Amount of Funding 
  

	4.1	The funding will be provided in the following form for the funding period referred to in Section 3: 

  

					
	 Type of funding
	  	Amount up to max.	 
	 Subsidy from FFG
	  	 	EUR  550,900.00	 
	 Loan from FFG
	  	 	EUR  432,900.00	 

  

			
	Terms of Loan	  	
	Interest rate	  	0.75% p.a. on current balance
	Repayment date:	  	03/31/2020
	Amount to be repaid:	  	EUR 432,900.00
	Collection of Interest and Principal:	  	by Direct Debit
	Interest Calculation:	  	every six months in arrears, or when loan falls due

  

	4.2	The grant percentage of the project is 50.0% of the project costs that qualify and can be demonstrated. The financing of the remainder of the costs of the project must be provided by the grant recipient. On the basis of
the information in the budget, the cash value of the grant is EUR 585,219.00, which is 29.7% in relation to the project costs that qualify under item 5.1. 

  

	4.3	The EU framework currently allows a level of subsidy by the state for Research, Development and Innovation of 45.0%. 

  

	4.4	Any reduction in expenditure on qualifying project costs will lead to a pro rata reduction in the subsidy. 

  

	4.5	The statement of the qualifying project costs under Section 5, as well as any interim or final report of costs do not imply, prior to checking by the FFG, any acceptance of the costs. The final level of the total
qualifying project costs and of the grant will only be determined after the conclusion of the project as part of the review of the accounts. 

  
 ./3 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43 (0)5 7755 - 0
 Fax +43 (0)5 7755 -
97900
 www.ffg.at.office@ffg.at
 Reg. Co.252263a Vienna Comm.
Court
	  	

 

 

			
	 Page 3
 number 856836/30000
	  	Project        

  

 Section 5 Qualifying Costs 

 

	5.1	The grant is based on the following qualifying project costs: 

  

					
	 Staff costs
	  	EUR	922,316.00	 
	 Cost of materials and overheads
	  	EUR	662,500.00	 
	 Third-party services
	  	EUR	357,600.00	 
	 Travel expenses
	  	EUR	25,375.00	 
		  	  
	  
	 
	 Total qualifying costs
	  	EUR	  1,967,791.00	 

  

	5.2	Qualifying costs are all the costs that are attributable to the project that arise directly, in fact and additionally (to the normal operating expenses) during the grant period defined in Section 3. Other
supplementary provisions relating to the qualifying costs can be found in the FFG Directive “KMU”, the Cost Guidelines and the Guidelines for Individual Projects for Experimental Development (each in the version referred in 14.1).

  

	5.3	Any significant modifications to the cost structure are subject to the prior written approval of FFG. 

  

	5.4	The VAT charged on the qualifying services cannot be funded. However, if this VAT can be shown to be actually paid as the final consumer by the grant recipient, meaning that they are not entitled to deduct any input
tax, then it will be treated as a qualifying cost element. 

 The grant provided by the Funding Body is a genuine subsidy, not
subject to VAT, as there is no exchange of goods or services, but instead a public interest in carrying out the activity of the research. 

The grant value is a gross amount. No additional, separate payments of any costs and taxes by FFG are permitted - for any reason whatsoever.

 The interest payable on the loan / the liability guarantee are subject to an exemption from VAT as per Section 6 para. 1 item 8 UStG
(Umsatzsteuergesetz [Value Added Tax Act]). 
  

	5.5	If the term for amortization (under Section 285 ABGB (Allgemeines Bürgerliches Gesetzbuch [General Civil Code])) of an item that is acquired for the project exceeds the period of the grant, the
depreciation costs qualify as per the Guidelines for Individual Projects for Experimental Development and the Cost Guidelines (each in the version listed under 14.1) for grants in the way defined there. 

 

	5.6	Grant funds from the Granting body, under the Einkommensteuergesetz [Income Tax Act 1988], Fed. Gazette number 400/1988 may not be used to created provisions or reserves. Grant funds are only to be used for the grant
application activities and aims. 

  

	5.7	The costs incurred by the grant recipient or his partners in preparing contracts or bank transfer costs must be borne by them and are not qualifying costs. 

 

	5.8	The granting body reserves the right to defer the disbursement of a grant, to reduce or to suspend it, if and for as long as circumstances exist that appear to show that the funded project is not being carried out in a
proper manner, (e.g. no schedule of costs is provided as defined). 

  
 ./4 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43 (0)5 7755 - 0
 Fax +43 (0)5 7755 -
97900
 www.ffg.at.office@ffg.at
 Reg. Co.252263a Vienna Comm.
Court
	  	

 

 

			
	 Page 4
 number 856836/30000
	  	Project        

  

	5.9	Grant funds that the FFG provides for the direct funding of science and research, to pay for costs or expenditure, come from public money and are therefore tax free under Section 3 para. 1 item 3 letter c) of the
EStG (Einkommensteuergesetz [Income Tax Act]) in combination with Section 3 para. 4 line 3 EStG. 

Section 6 Conditions and Duties 
  

	6.1	Special, project-specific conditions and duties 

  

	 	1.	For Ms. Redl only the costs for the patent application are to be subsidized. 

  

	 	2	The grant is subject to the continued existence of the Development location including staff and IP rights until at least 06/30/2022. 

 

	6.2	The original, signed grant agreement must be returned to the granting body at the latest 4 weeks after receipt. 

  

	6.3	By signing this grant agreement, the grant recipient undertakes that they will keep the granting body informed - at the latest by means of the required reports - of all requested and/or approved public grants that
relate either directly or indirectly to this project. 

 Section 7 Disbursement of the Grant 

 

	7.1	The disbursement of the 1st installment, totaling 50% of the agreed grant funds will be made after conclusion of the Grant Agreement and fulfillment of the agreed conditions and duties set out in Section 6.

 The second installment of 30% will be disbursed on approval of an interim report, which must provide proof of 50% of the
approved total costs, and on fulfillment of the conditions and duties in Section 6. 
 The disbursement of the final installment of 20%
of the total approved grant funding will be made only after completion of all conditions and duties (final accounts, final report, etc.) and after checking and approval of the proofs of expenditure (acceptance of accounts) by the FFG. 

 

	7.2	The transfer will be made to the following account held by the grant recipient 

 Account holder:
            ARSANIS Biosciences GmbH 
 Bank name:
                   
 IBAN:
                           

BIC/SWIFT:                  

Section 8 Reporting Requirements 
  

	8.1	The grant recipient shall report to FFG in accordance with Section 3 of the general grant terms on the execution of the subsidized project, by submitting professional reports (interim and final reports) and
accounts. The reports and accounts must be submitted via eCall (https://ecall.ffg.at). The forms provided in eCall must be used. On request, other documents may also need to be submitted to FFG. 

 

	8.2.1	Where a grant is given for prototypes the grant recipient must inform FFG of the location or the future use of the prototype(s). 

  
 ./5 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43 (0)5 7755 - 0
 Fax +43 (0)5 7755 -
97900
 www.ffg.at.office@ffg.at
 Reg. Co.252263a Vienna Comm.
Court
	  	

 

 

			
	 Page 5
 number 856836/30000
	  	Project        

  

 Section 9 Amendments to the Agreement 

 

	9.1	Amendments to the present agreement may only be made explicitly and in writing. This also applies to any variation of this provision. 

 

	9.2	Subsequent amendments to the agreed conditions and duties may, if necessary because of the existence of special circumstances, be mutually agreed in the form of written addenda, and subject to renewed approval by the
Advisory Board. 

 Section 10 Liability 
  

	10.1	The grant recipient accepts full liability vis a vis the FFG, for compliance with all contractual provisions. The grant recipient is also liable for the actions of third parties whom he represents (e.g. owners, company
bodies, etc.). The grant recipient shall indemnify the FFG for any claims by third parties. 

 Section 11 Severability
Clause 
  

	11.1	Should a provision of this grant agreement prove to be invalid, the validity of the other provisions of the grant agreement remain unaffected. The parties to the agreement undertake to replace the invalid provision with
one that comes as close as possible to the intent of this grant agreement. 

 Section 12 Applicable Law 

 

	12.1	This agreement and all its Annexes are subject to Austrian Law, excluding the referral standards of Austrian international private law. 

Section 13 Jurisdiction 
  

	13.1	The jurisdiction for all and any legal disputes arising from the grant is agreed to be the relevant court of jurisdiction in Vienna. The FFG retains the right to also sue the grant recipient at the latter’s normal
place of jurisdiction. 

 Section 14 Components of the Agreement 

 

	14.1	The following documents represent the total components of the grant agreement: 

  

	 	•	 	the grant application submitted via eCall (“Development of antibody-based therapeutics for the treatment of life threatening pneumococcal disease”) in the version dated 05/12/2016 

 

	 	•	 	General grant conditions for grant agreements, in its current form (2015 Version) 

  

	 	•	 	Guidelines for individual projects for experimental development, Version 3 .1 

  

	 	•	 	Cost Guidelines Version 2.0 

  

	14.2	The legal bases for this grant agreement are specifically: 

  

	 	•	 	The Österreichische Forschungsförderungsgesellschaft mbH-Errichtungsgesetz [law creating the Austrian Research Grant Company]) (Forschungsförderungs Strukturreformgesetz [Research Support Structural
Reform Law]) each in their current version 

  
 ./6 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43 (0)5 7755 - 0
 Fax +43 (0)5 7755 -
97900
 www.ffg.at.office@ffg.at
 Reg. Co.252263a Vienna Comm.
Court
	  	

 

 

			
	 Page 6
 number 856836/30000
	  	Project        

  

	 	•	 	EU framework for state subsidies to promote Research, Development and Innovation (OJ C 198 dated 06/27/2014) 

  

	 	•	 	Commission Regulation (EU) 651/2014 dated June 17, 2014 declaring certain categories of aid compatible with the internal market in application of Articles 107 and 108 of the Treaty on the Functioning of the
European Union (TFEU 2014) 

  

	 	•	 	Directive for the Österreichische Forschungsförderungsgesellschaft mbH [Austrian Research Support Company] to further applied research, development and innovation (FFG-Directive “KMU” GZ: BMVIT-
609.986/0012-III/I2/2014 and BMWFW-98.310/0102-C1/10/2014). This Directive was submitted on the basis of TFEU 2014 to the European Commission for exemption. 

The grant recipient confirms that they have knowledge of all parts of the agreement and accepts them unreservedly and is aware that non-compliance with the
above provisions of the agreement can lead to a possible demand to return the grant monies. 
 The grant recipient confirms that no pending demands for
return of monies by the European Commission currently exist, and that no retroactive demand of incompatible subsidies will be entertained. 
 The grant
recipient gives its permission to use the data listed under Art. 9 para.1 TFEU (EU Regulation number 651/ 2014) Annex III for a publication of information, provided the cash value of the grant (gross subsidy equivalent) exceeds EUR 500,000.00. 

 

			
	For the Granting Body:	  	
	Österreichische Forschungsförderungsgesellschaft mbH (FFG)	  	[stamp:] Österreichische
		  	              Forschungsförderungsgesellscha
	Vienna, on 06/27/2016	  	              ft mbH (FFG)

  

			
	 /s/ Dr. Henrietta Egerth-Stadlhuber
	  	 /s/ Dr. Klaus Pseiner

	Dr. Henrietta Egerth-Stadlhuber	  	Dr. Klaus Pseiner
	Managing Director	  	Managing Director

  

			
	Grant Recipient	  	
		  	ARSANIS
	Vienna, on 07/14/2016	  	Biosciences GmbH
		  	MarxBox
	 /s/ Dr. Eszter Nagy
	  	Helmut-Qualtinger-Gasse 2
	(Authorized signature, please add name and job-title in block capitals)	  	1030 Vienna

 Dr. Eszter Nagy 
 Managing
Director 

  
 ./7 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43 (0)5 7755 - 0
 Fax +43 (0)5 7755 -
97900
 www.ffg.at.office@ffg.at
 Reg. Co.252263a Vienna Comm.
Court
	  	

 

 

			
	 Page 7
 number 856836/30000
	  	Project        

  

 Annexes: 

Directive for the Österreichische Forschungsförderungsgesellschaft mbH to further applied research, development and innovation (FFG-Directive
“KMU”) 
 via link https://www.ffg.at/recht-finanzen/rechtsgrundlagen 

General grant conditions for grant agreements in current form (2015 Version) 

Guidelines for individual projects for experimental development, Version 3.1 

Cost Guidelines Version 2.0 

  
  

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse 1

1090 Vienna
	  	 Tel +43 (0)5 7755 - 0
 Fax +43 (0)5 7755 -
97900
 www.ffg.at.office@ffg.at
 Reg. Co.252263a Vienna Comm.
Court

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]